Fig. 2
From: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Icaritin-based nanomedicines for improved immunotherapy of advanced HCC. Smart drug delivery systems including stimuli-responsive nanocarriers, cell membrane-coated nanocarriers, and living cell-nanocarrier systems, can be designed to load icaritin. The formed icaritin-based nanomedicines show improved bioavailability and delivery efficiency as well as alleviated immunogenicity. Icaritin-based nanomedicines could enhance the immunotherapy of advanced HCC by improving drug solubility and stability, prolonging blood circulation, augmenting targeted accumulation, elevating tumor penetration and controlling drug release. Part of this figure was created partially utilizing the templates on https://smart.servier.com/ as a reference. HCC hepatocellular carcinoma, RES reticuloendothelial system